Literature DB >> 29113905

Tripartite motif-containing (TRIM) 21 negatively regulates intestinal mucosal inflammation through inhibiting TH1/TH17 cell differentiation in patients with inflammatory bowel diseases.

Guangxi Zhou1, Wei Wu1, Lin Yu1, Tianming Yu1, Wenjing Yang1, Ping Wang2, Xiaoping Zhang3, Yingzi Cong4, Zhanju Liu5.   

Abstract

BACKGROUND: Tripartite motif-containing (TRIM) 21 has been implicated in the pathogenesis of several types of autoimmune diseases.
OBJECTIVE: We sought to elucidate TRIM21 expression in patients with inflammatory bowel diseases (IBDs) and its role in regulating intestinal mucosal inflammation.
METHODS: TRIM21 expression was analyzed in the inflamed mucosa of patients with IBDs by means of quantitative RT-PCR and immunohistochemistry. Peripheral blood CD4+ T cells were transfected with lentivirus-expressing TRIM21 (LV-TRIM21) or LV-sh-TRIM21, and cytokine expression was determined by using quantitative RT-PCR and ELISA. TRIM21-/- mice were generated, and trinitrobenzene sulfonic acid- and CD45RBhighCD4+ T cell-induced colitis models were established to determine its role in induction of intestinal inflammation.
RESULTS: TRIM21 was expressed predominantly in CD4+ T cells and decreased markedly in the inflamed mucosa of patients with IBDs compared with healthy control subjects. Ectopic expression of TRIM21 inhibited IBD CD4+ T cells to differentiate into TH1 and TH17 cells, whereas downregulation of TRIM21 had the opposite effects. TRIM21-/- mice had more severe colitis after administration of trinitrobenzene sulfonic acid compared with wild-type mice, which was characterized by increased expression of IFN-γ, TNF-α, and IL-17A in the colon. TRIM21-/-CD45RBhighCD4+ T cells reconstituted into recombination-activating gene (Rag1)-/- mice induced more severe colitis than in wild-type control mice. Mechanistically, interferon regulatory factor 3 was identified as a functional downstream target of TRIM21 in that silencing of interferon regulatory factor 3 suppressed TRIM21-/-CD4+ T-cell differentiation into TH1 and TH17 cells.
CONCLUSIONS: TRIM21 plays a protective role in mucosal inflammation through inhibiting TH1 and TH17 cell differentiation. Thus TRIM21 might serve as a potential therapeutic target for the treatment of IBDs.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4(+) T cells; T(H)1; T(H)17; Tripartite motif-containing 21; inflammatory bowel disease; mucosal inflammation

Mesh:

Substances:

Year:  2017        PMID: 29113905     DOI: 10.1016/j.jaci.2017.09.038

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  17 in total

1.  TRIM21 regulates pyroptotic cell death by promoting Gasdermin D oligomerization.

Authors:  Wenqing Gao; Yuanyuan Li; Xuehe Liu; Sen Wang; Pucheng Mei; Zijun Chen; Kewei Liu; Suhua Li; Xue-Wei Xu; Jianhua Gan; Jiaxue Wu; Chaoneng Ji; Chen Ding; Xing Liu; Yuping Lai; Housheng Hansen He; Judy Lieberman; Hao Wu; Xiangjun Chen; Jixi Li
Journal:  Cell Death Differ       Date:  2021-09-11       Impact factor: 12.067

2.  TRIM58 Restrains Intestinal Mucosal Inflammation by Negatively Regulating TLR2 in Myeloid Cells.

Authors:  Annette Eyking; Frederike Ferber; Stefanie Köhler; Henning Reis; Elke Cario
Journal:  J Immunol       Date:  2019-08-05       Impact factor: 5.422

3.  [TRIM59 regulates invasion and migration of nasopharyngeal carcinoma cells by targeted modulation of PPM1B].

Authors:  W Wang; L Zhou; Z Sun; J Wu; Y Cui
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-07-20

4.  Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.

Authors:  Jonathan J Cho; Zhiwei Xu; Upasana Parthasarathy; Theodore T Drashansky; Eric Y Helm; Ashley N Zuniga; Kyle J Lorentsen; Samira Mansouri; Joshua Y Cho; Mariola J Edelmann; Duc M Duong; Torben Gehring; Thomas Seeholzer; Daniel Krappmann; Mohammad N Uddin; Danielle Califano; Rejean L Wang; Lei Jin; Hongmin Li; Dongwen Lv; Daohong Zhou; Liang Zhou; Dorina Avram
Journal:  Nat Commun       Date:  2019-02-11       Impact factor: 14.919

5.  Cyclosporine modulates neutrophil functions via the SIRT6-HIF-1α-glycolysis axis to alleviate severe ulcerative colitis.

Authors:  Huiying Lu; Jian Lin; Chunjin Xu; Mingming Sun; Keqiang Zuo; Xiaoping Zhang; Mingsong Li; Hailiang Huang; Zhong Li; Wei Wu; Baisui Feng; Zhanju Liu
Journal:  Clin Transl Med       Date:  2021-02

6.  Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis.

Authors:  Spyridon Megremis; Thomas D J Walker; Xiaotong He; James O'Sullivan; William E R Ollier; Hector Chinoy; Neil Pendleton; Antony Payton; Lynne Hampson; Ian Hampson; Janine A Lamb
Journal:  Commun Biol       Date:  2021-03-26

7.  MicroRNA-219a-5p suppresses intestinal inflammation through inhibiting Th1/Th17-mediated immune responses in inflammatory bowel disease.

Authors:  Yan Shi; Shenglan Dai; Caiyu Qiu; Tao Wang; Yong Zhou; Cuihua Xue; Jun Yao; Yaping Xu
Journal:  Mucosal Immunol       Date:  2019-10-18       Impact factor: 7.313

8.  Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners.

Authors:  Eunate Gallardo-Vara; Lidia Ruiz-Llorente; Juan Casado-Vela; María J Ruiz-Rodríguez; Natalia López-Andrés; Asit K Pattnaik; Miguel Quintanilla; Carmelo Bernabeu
Journal:  Cells       Date:  2019-09-13       Impact factor: 6.600

9.  LRCH1 suppresses migration of CD4+ T cells and refers to disease activity in ulcerative colitis.

Authors:  Yibo Wang; Hairong Zhang; Heng He; Kuankuan Ai; Wei Yu; Xiao Xiao; Yufen Qin; Lingming Zhang; Huabao Xiong; Guangxi Zhou
Journal:  Int J Med Sci       Date:  2020-02-17       Impact factor: 3.738

10.  Knockdown of TRIM8 Attenuates IL-1β-induced Inflammatory Response in Osteoarthritis Chondrocytes Through the Inactivation of NF-κB Pathway.

Authors:  Ruoxi Liu; Hao Wu; Huanjin Song
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.